General Updates

Date: October 08, 2026 Ref. No.: KDL/SE/053/2026-27 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001. Mumbai – 400051 Scrip Code: 543328 NSE Symbol: KRSNAA Dear Sir/Madam, Sub: Intimation of receipt of In-principle Approval received from BSE Limited and National Stock Exchange of India Limited for issue of 16,21,000 convertible warrants on Preferential basis in terms of Regulation 28(1) to the Promoter and Promoter Group of the Company Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 "SEBI (LODR)", we wish to inform you that the Company has received In-principle Approval from BSE Limited and National Stock Exchange of India Limited ('the Exchanges') vide letters nos. LOD/PREF/PB/FIP/908/2026- 27 and NSE/LIST/56990 respectively, for issue of 16,21,000 warrants convertible into 16,21,000 Equity shares of face value Rs. 5/- each at an issue price of Rs. 566/- each to the Promoter and Promoter Group of the Company on preferential basis in terms of Regulation 28(1). A copy of the in-principle approval letter received from NSE is enclosed herewith. The in- principle approval letter received from BSE contains certain factual errors that require rectification. Accordingly, the corrected letter will be intimated to the Exchanges separately upon its receipt. The above information will also be available on the website of the Company at https://krsnaadiagnostics.com/investors/. You are requested to take the above information on record. Thanking you, Yours sincerely For Krsnaa Diagnostics Limited Sujoy Sudipta Bose Company Secretary & Compliance Officer Encl: as above Ref: NSE/LIST/56990 October 08, 2026 The Company Secretary Krsnaa Diagnostics Limited Dear Sir/Madam, Sub: In - Principle approval under Regulation 28(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 We are in receipt of your application regarding In-principle approval for issue of 16,21,000 Equity shares of Rs. 5/- each issued pursuant to conversion of warrants issued on Preferential basis in terms of Regulation 28(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. In this regard, the Exchange is pleased to grant in-principle approval for the said issue subject to the Company fulfilling the following conditions: 1. Filing the listing application at the earliest from the date of allotment. 2. Receipt of statutory and other approvals and compliance of guidelines/regulations issued by the statutory authorities including SEBI, RBI, MCA, etc. 3. Compliance with all the applicable guidelines, regulations, directions of the Exchange or any statutory authorities as on the date of listing application. 4. Compliance of all conditions as per the SEBI (LODR) Regulations, 2015 as on date of listing, Companies Act, 1956 / Companies Act, 2013 and other applicable laws. 5. Submissions of documents as may be required by NSE and payment of applicable fees. Further, the company is advised to strengthen internal controls (to monitor trades being executed by the proposed allottees in the scrip of the company) before allotment of securities in order to avoid any non-compliances in respect of trades being executed by the allottees in contravention of provisions of Chapter V of SEBI (ICDR) Regulations. In this regard, a) The Company is advised to obtain an undertaking from the allottee(s) confirming that they shall not do intra-day trading in the scrip of the company or any sale in the scrip of the company till the allotment date of the security as required under SEBI (ICDR) Regulations. b) The Company may note that the responsibility/onus is solely on the Issuer company to verify the above (a) and ensure compliance with applicable provisions including Regulation 167(6) of SEBI ICDR regulations, 2018. c) The Company may also note that any non-compliances, if observed by the exchanges post the undertaking and verification by the Issuer company may impact the listing of such shares. Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any. This Document is Digitally Signed Signer: POOJA RISHIKESH PASHTE Date: Thu, Oct 8, 2026 13:49:36 IST Location: NSE The Exchange reserves its right to withdraw its in-principle approval at a later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations, 2015, Guidelines/ Regulations issued by statutory authorities, etc. Yours faithfully, For National Stock Exchange of India Limited Pooja Pashte Manager National Securities Depository Limited Central Depository Services Limited P.S. Checklist of all the further issues is available on website of the exchange at the following URL: https://www.nseindia.com/static/companies-listing/raising-capital-further-issues-main- sme-checklist The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application. The app can be downloaded from the App Store/ Play store with the name “NEAPS APP” This Document is Digitally Signed Signer: POOJA RISHIKESH PASHTE Date: Thu, Oct 8, 2026 13:49:36 IST Location: NSE